Edesa Biotech, INC Form 4 insider transactions

Edesa Biotech's CEO, Pardeep Nijhawan, has reported the acquisition of 270,844 restricted share units through recent grants, significantly increasing his direct and indirect beneficial ownership in the company.

Edesa Biotech, Inc. Director Sean Arthur MacDonald has reported the acquisition of 20,001 restricted share units, vesting over twelve months, as part of the company's 2019 Equity Incentive Compensation Plan.

Edesa Biotech, Inc. Director Joan Chypyha was granted 11,000 restricted share units as part of the company's 2019 Equity Incentive Compensation Plan, vesting over 12 months.

Edesa Biotech, Inc. President Michael J. Brooks was granted 207,201 restricted share units, vesting over 18 and 36 months, as reported in a recent SEC Form 4 filing.

Edesa Biotech's Chief Financial Officer, Peter J. Weiler, was granted 65,000 restricted share units as part of the company's 2019 Equity Incentive Compensation Plan.

Edesa Biotech, Inc. Director Da David Liu was granted 5,501 restricted share units as part of the company's 2019 Equity Incentive Compensation Plan.

Pardeep Nijhawan, CEO of Edesa Biotech, reports acquiring 6,392 common shares through a grant of restricted share units and grants power of attorney to Peter J. Weiler for SEC filings.

Pardeep Nijhawan, CEO of Edesa Biotech, reports acquisition and disposal of common shares, including a grant of restricted share units.

Pardeep Nijhawan, CEO of Edesa Biotech, reports the acquisition of 6,339 common shares through a grant of restricted share units and updates on beneficial ownership.

Carlo Sistilli, a director of Edesa Biotech, purchased 10,416 common shares in a private placement at $1.92 per share.

Edesa Biotech's CEO, Pardeep Nijhawan, purchased $1 million worth of Series B-1 Convertible Preferred Shares in a private placement.

Patrick Marshall, a director of Edesa Biotech, purchased 41,666 common shares in a private placement at $1.92 per share.

Edesa Biotech's CEO, Pardeep Nijhawan, reports acquiring 8,264 common shares through a grant of restricted share units, while also disclosing indirect ownership through various entities and a family trust.

Pardeep Nijhawan, CEO of Edesa Biotech, reports acquiring 8,476 common shares through a grant of restricted share units.

Edesa Biotech CEO Pardeep Nijhawan reports the acquisition of 6,420 common shares through a grant of restricted share units and discloses indirect ownership of additional shares through various entities.

Edesa Biotech's CEO, Pardeep Nijhawan, received a grant of 4,630 common shares, while maintaining indirect ownership through various entities.

Edesa Biotech's CEO, Pardeep Nijhawan, purchased Series A-1 Convertible Preferred Shares and warrants in a private placement, potentially increasing his stake in the company.

Pardeep Nijhawan, CEO of Edesa Biotech, reports acquiring 3,300 common shares through the company's 2019 Equity Incentive Compensation Plan.

Edesa Biotech CEO Pardeep Nijhawan reports the acquisition of 3,055 common shares through a grant of restricted share units.

Edesa Biotech CEO Pardeep Nijhawan reports the acquisition of 3,317 common shares through restricted share units, increasing his direct and indirect beneficial ownership.

Edesa Biotech's CEO, Pardeep Nijhawan, acquired 4,015 common shares through vested restricted share units on July 2, 2024, according to a Form 4 filing.

CEO Pardeep Nijhawan reports acquisition of 4,785 common shares of Edesa Biotech, Inc. through a grant of restricted share units.

Edesa Biotech CEO Pardeep Nijhawan reports acquisition of 3,083 common shares through a vested restricted share unit grant.

Edesa Biotech's CEO, Pardeep Nijhawan, reports acquiring 3,253 common shares through a grant of restricted share units.

Edesa Biotech's CEO, Pardeep Nijhawan, reports the acquisition of 5,000 common shares at $4, along with adjustments to indirect ownership through various entities and trusts.

Edesa Biotech's CEO, Pardeep Nijhawan, reports acquiring 2,765 common shares through a grant of restricted share units, bringing his total direct holdings to 107,810 shares.